Source link : https://www.newshealth.biz/health-news/first-in-class-b-cell-depleting-agent-promising-for-mg/
SAVANNAH, Georgia — Inebilizumab, a first-in-class anti-CD19 B-cell depleting agent, demonstrated both safety and superior efficacy compared with placebo in patients with seropositive generalized myasthenia gravis (gMG), new phase 3 data showed. “Based on these results, we have demonstrated that targeting B cells, including the antibody-secreting cells, is beneficial, and there is likely a role […]
Author : News Health
Publish date : 2024-10-17 09:28:37
Copyright for syndicated content belongs to the linked Source.
